swisspartners Ltd. acquired a new stake in cbdMD, Inc. (NYSEAMERICAN:YCBD) during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 120,000 shares of the company’s stock, valued at approximately $501,000.
Several other large investors have also made changes to their positions in the company. AdvisorShares Investments LLC lifted its stake in shares of cbdMD by 58.7% in the 1st quarter. AdvisorShares Investments LLC now owns 2,284,128 shares of the company’s stock worth $9,456,000 after acquiring an additional 844,403 shares during the period. BlackRock Inc. increased its position in cbdMD by 58.2% during the 1st quarter. BlackRock Inc. now owns 722,713 shares of the company’s stock worth $2,992,000 after purchasing an additional 265,825 shares during the period. Penserra Capital Management LLC raised its stake in shares of cbdMD by 128.0% during the 4th quarter. Penserra Capital Management LLC now owns 222,334 shares of the company’s stock worth $654,000 after buying an additional 124,812 shares in the last quarter. Davy Global Fund Management Ltd raised its stake in shares of cbdMD by 227.5% during the 1st quarter. Davy Global Fund Management Ltd now owns 161,283 shares of the company’s stock worth $668,000 after buying an additional 112,035 shares in the last quarter. Finally, Squarepoint Ops LLC raised its stake in shares of cbdMD by 43.3% during the 4th quarter. Squarepoint Ops LLC now owns 133,665 shares of the company’s stock worth $394,000 after buying an additional 40,377 shares during the last quarter. 19.34% of the stock is owned by institutional investors and hedge funds.
NYSEAMERICAN:YCBD traded up $0.02 during trading hours on Friday, reaching $3.32. 2,091 shares of the company traded hands, compared to its average volume of 792,538. The company has a debt-to-equity ratio of 0.01, a quick ratio of 4.43 and a current ratio of 5.06. The firm’s 50-day simple moving average is $2.88. The stock has a market capitalization of $187.31 million, a PE ratio of -4.34 and a beta of 1.72. cbdMD, Inc. has a 1-year low of $1.41 and a 1-year high of $6.83.
Separately, Zacks Investment Research upgraded shares of cbdMD from a “sell” rating to a “hold” rating in a report on Thursday, April 1st.
cbdMD Company Profile
cbdMD, Inc produces and distributes various cannabidiol (CBD) products. It owns and operates consumer hemp-based CBD brands, such as cbdMD and Paw CBD. Its cbdMD brand products include CDB tinctures, gummies, topicals, capsules, bath bombs, bath salts, and sleep aids. The company also offers veterinarian-formulated products, including tinctures, chews, and topicals under the Paw CBD brand name.
Further Reading: What economic reports are most valuable to investors?
Want to see what other hedge funds are holding YCBD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for cbdMD, Inc. (NYSEAMERICAN:YCBD).
Receive News & Ratings for cbdMD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for cbdMD and related companies with MarketBeat.com's FREE daily email newsletter.